Merck Confident About Keytruda/Chemo Combo May Date With FDA

Keytruda's share in first-line lung cancer in the US is growing, but Merck's first-quarter sales for the PD-1 inhibitor were below consensus. Future growth may depend on combination treatment with chemotherapy, which the company is confident about the FDA approving this month.